Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Commentary

Free Access

The Heart of Drug Discovery and Development: Rational Target Selection

Spector R.a · Vesell E.S.b

Author affiliations

aRobert Wood Johnson Medical School, New Brunswick, N.J., and Harvard-MIT Program in the Health Sciences, Cambridge, Mass., and bDepartment of Pharmacology, Pennsylvania State University College of Medicine, Hershey, Pa., USA

Corresponding Author

Elliot S. Vesell, M.D.

Department of Pharmacology, Pennsylvania State University College of Medicine

500 University Drive

Hershey, PA 17033 (USA)

Tel. +1 717 531 8285, Fax +1 717 531 5013, E-Mail esvl@psu.edu

Related Articles for ""

Pharmacology 2006;77:85–92

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Abstract

Critical to the discovery and development of drugs and vaccines is the rational selection of biochemical, immunologic or molecular targets. To understand the rationale for target selection, we review strengths and weaknesses of the four main approaches: whole animal disease models; molecular targeting; epidemiology/observation studies, and genomics. After classifying diseases into those with a relatively stable pathophysiology (e.g., hypertension and gout) versus those with an unstable pathophysiology (e.g., AIDS and influenza) to aid in understanding target selection, we provide examples of successful and unsuccessful selection of drug and vaccine targets, focusing on the molecular and epidemiological/observational approaches. We discuss the reasons that molecular targeting has led to successful control of many diseases, whereas the epidemiological/observational approach has had a checkered history. We also assess the potential power of the genomic approach, specifically the curative versus controlling/preventive strategies. With combined genetic and molecular approaches and judicious use of whole animal models and properly performed epidemiology/observation studies to select the appropriate targets, the future for controlling, preventing and even curing many diseases is very bright indeed.

© 2006 S. Karger AG, Basel


References

  1. Spector R: Progress in the search for ideal drugs. Pharmacology 2002;64:1–7.
  2. Spector R, Vesell ES: The pursuit of truth: role of epidemiology/observation studies. J Clin Pharmacol 2000;40:1205–1210.
  3. Spector R, Vesell ES: Which studies of therapy merit credence? Vitamin E and estrogen as cautionary examples. J Clin Pharmacol 2002;42:955–962.
  4. Spector R, Vesell ES: A rational approach to the selection of drugs for clinical practice. Pharmacology 2002;65:57–61.
  5. Spector R, Vesell ES: The power of pharmacological sciences: the example of the proton pump inhibitors. Pharmacology 2006;76:148–156.
  6. Rebec GV, Barton SJ, Ennis MD: Dysregulation of ascorbate release in striatum of behaving mice expressing the Huntington’s disease gene. J Neurosci 2002;22:RC202.
  7. Vagelos R, Galambos L: Medicine, Science and Merck. Cambridge, Cambridge University Press, 2004.
  8. Rundles RW, Wyngaarden JB, Hitchings GH, Elion GB: Drugs and uric acid. Ann Rev Pharmacol 1969;9:345–362.
  9. Black JW, Duncan WAM, Durant CJ, Ganellin CP, Parsons EM: Definition and antagonism of histamine H2-receptors. Nature 1972;236:385–390.
  10. Enomoto A, Kimura H, Chairoungdua A, et al: Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature 2002;417:447–451.
  11. Ichioka K, Hosoyamada M, Hisatome I, et al: Clinical and molecular analysis of patients with renal hypouricemia in Japan – influence of URAT-1 gene on urinary urate excretion. J Am Soc Nephrol 2004;15:164–173.
  12. Veterans Administration Cooperative Study Group: Effects of treatment on morbidity in hypertension. JAMA 1967;202:1028–1034.
    External Resources
  13. Spector R: The Scientific Basis of Clinical Pharmacology: Principles and Examples. Boston, Little Brown, 1986.
  14. Jackson EK: Renin and angiotension; in Brunton LL (ed): Goodman and Gilman’s the Pharmacological Basis of Therapeutics. New York, McGraw-Hill, 2006, pp 789–821.
  15. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvistatin Survival Study (4S). Lancet 1994;344:1383–1389.
  16. Baigent C, Keech A, Kearney PM, et al, Cholesterol Treatment Trialists’ (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267–1278.
  17. Opie LH: Controversies in cardiology. Lancet 2006;367:13–14.
  18. Spake D: The menopausal marketplace. US News World Rep 2002;133:42–50.
    External Resources
  19. Cauley JA, Robkins J, Chen Z, et al: Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003;290:1729–1738.
  20. Raisz LG: Pathogenesis of osteoporosis: concepts, conflicts and prospects. J Clin Invest 2005;115:3318–3325.
  21. McClung MR, Lewiecki EM, Cohen SB, et al, AMG 162 Bone Loss Study Group: Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821–831.
  22. Liddle R, Gertz BJ, Kansyama S: Effect of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. J Clin Invest 1989;84:1220–1225.
  23. Anderson GL, Limacher M, Assaf AR, et al, Women’s Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;29:1701–1712.
  24. Brown BG, Crowley J: Is there any hope for vitamin E. JAMA 2005;293:1387–1390.
  25. Howard BV, Van Horn L, Hsia J, et al: Low-fat dietary pattern and risk of cardiovascular disease: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006;295:655–666.
  26. Beresford SAA, Johnson KL, Ritenbaugh C, et al: Low-fat dietary pattern and risk of colorectal cancer: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006;295:643–654.
  27. Prentice RL, Cann B, Chlebowski RW, et al: Low-fat dietary pattern and risk of invasive breast cancer: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006;295:629–642.
  28. Jackson RD, LaCroix AZ, Gass M, et al, Women’s Health Initiative Investigators: Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669–683.
  29. Wactawski-Wende J, Kotchen JM, Anderson GL, et al, Women’s Health Initiative Investigators: Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684–696.
  30. Davey Smith G, Ebrahim S: Folate supplementation and cardiovascular disease. Lancet 2005;366:1679–1681.
  31. Bonaa KH, Njolstad I, Ueland PM, et al: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578–1588.
  32. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567–1577.
  33. Col NF, Pauker SG: The discrepancy between observational and randomized trials of menopausal hormone therapy: did expectations shape experience? Ann Intern Med 2003;139:923–929.
  34. Ioannidis JPA: Contradicted and initially stronger effects in highly cited clinical research. JAMA 2005;294:218–228.
  35. Sempos CT: Some limitations of semiquantitative food frequency questionnaires. Am J Epidemiol 1992;135:1127–1132.
    External Resources
  36. Grodstein F, Manson JE, Stampfer M: Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35–44.
  37. Hsia J, Langer RD, Manson JE: Conjugated equine estrogens and coronary heart disease. Arch Intern Med 2006;166:357–365.
  38. Editorial: Low-fat diets flub a test. NY Times 2006;Feb 9:A26.
  39. McConnell JD, Bruskewitz R, Walsh P, et al: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338:557–563.
  40. Roehrborn CG, Marks LS, Fenter T, et al: Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004;63:709–715.

Article / Publication Details

First-Page Preview
Abstract of Commentary

Received: March 16, 2006
Accepted: March 23, 2006
Published online: June 02, 2006
Issue release date: May 2006

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 5

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.